STOCKWATCH
·
Other Pharmaceuticals
Quarterly ResultMay 7, 2026, 05:13 PM

Nu Skin Q1 Revenue $320.6M, Adj. EPS $0.14; Maintains FY26 Outlook

AI Summary

Nu Skin Enterprises reported first-quarter 2026 revenue of $320.6 million, a 12.0% decrease year-over-year, with adjusted diluted EPS of $0.14. The company met its revenue expectations and made progress on strategic priorities, including the rollout of Prysm iO and expansion into emerging markets like India. Nu Skin also returned $8 million to shareholders through dividends and share repurchases and refinanced its debt.

Key Highlights

  • Q1 2026 revenue was $320.6 million, a 12.0% decrease year-over-year.
  • Q1 2026 adjusted diluted EPS was $0.14, compared to $0.23 in the prior-year quarter.
  • Total Customers decreased by 14% to 669,535, and Sales Leaders decreased by 13% to 26,915.
  • The company returned $2.9 million in dividends and $5.0 million in stock repurchases to shareholders.
  • Nu Skin refinanced its debt, extending liquidity.
  • Q2 2026 revenue guidance is $330 million to $360 million, with EPS of $0.15 to $0.25.
  • Full-year 2026 adjusted EPS guidance is maintained at $0.80 to $1.20.
  • Anticipates formal launch of India market in late 2026.
NUS
Other Pharmaceuticals
NU SKIN ENTERPRISES, INC.

Price Impact